文献速递糖尿病

达格列净改善伴白蛋白尿的2型糖尿病患者的尿液蛋白质组肾脏风险分类器CKD273:一项随机临床试验

Dapagliflozin Improves the Urinary Proteomic Kidney-Risk Classifier CKD273 in Type 2 Diabetes with Albuminuria: A Randomized Clinical Trial.
PubMed 文献 · Diabetes Care · 2022-01-01

在伴白蛋白尿的2型糖尿病患者中开展的随机双盲交叉试验显示,与安慰剂相比,达格列净治疗12周显著降低尿液蛋白质组肾脏风险分类器CKD273评分(-0.221;95% CI -0.356, -0.087;P=0.002),且达格列净治疗后呈高风险模式者14例,安慰剂后24例(P=0.021)。

要点

  • 达格列净较安慰剂显著降低CKD273评分(-0.221;95% CI -0.356, -0.087;P=0.002)。
  • 达格列净后高风险CKD273模式14例,安慰剂后24例(P=0.021)。
  • 结论为达格列净在肾素-血管紧张素系统抑制基础上降低CKD273,为后续研究CKD273作为可干预肾脏风险因素铺路。

核心结论

  • 在伴白蛋白尿的2型糖尿病患者中,在肾素-血管紧张素系统抑制基础上加用达格列净可降低尿液蛋白质组分类器CKD273,为后续研究CKD273作为可干预肾脏风险因素铺路。

研究设计与样本

  • 双盲、随机、对照、交叉试验,纳入2型糖尿病且尿白蛋白与肌酐比值(UACR)≥30 mg/g的参与者,随机接受达格列净或匹配安慰剂,加于指南推荐治疗之上(ClinicalTrial.gov标识NCT02914691)。
  • 治疗期为12周,随后交叉至对侧治疗;主要结局为CKD273评分变化;次要结局包括使用预设切点评分0.154从高风险向低风险CKD273模式的回归。
  • 共随机40例参与者,32例完成试验且蛋白质组测量完整;28例(88%)为男性,基线平均(标准差)年龄63.0(8.3)岁,平均(标准差)糖尿病病程15.4(4.5)年,平均HbA1c为73(14)mmol/mol(8.8%[1.3%]),中位数(四分位距)UACR为154(94, 329)mg/g。

主要发现

  • 达格列净较安慰剂显著降低CKD273评分(-0.221;95% CI -0.356, -0.087;P=0.002)。
  • 达格列净治疗后14例参与者呈高风险模式,安慰剂后24例(P=0.021)。

关键数值与推荐

  • 主要结局采用配对t检验比较达格列净与安慰剂治疗后终点间CKD273评分。
  • 风险类别回归采用McNemar检验评估,预设切点评分为0.154。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on the kidney-risk urinary proteomic classifier (CKD273) in persons with type 2 diabetes (T2D) and albuminuria. RESEARCH DESIGN AND METHODS: In a double-blind, randomized, controlled, crossover trial, we assigned participants with T2D and urinary albumin to creatinine ratio (UACR) ≥30 mg/g to receive dapagliflozin or matching placebo added to guideline-recommended treatment (ClinicalTrial.gov identifier NCT02914691). Treatment periods lasted 12 weeks, when crossover to the opposing treatment occurred. The primary outcome was change in CKD273 score. Secondary outcomes included regression from high-risk to low-risk CKD273 pattern using the prespecified cutoff score of 0.154. The primary outcome was assessed using paired t test between end-to-end CKD273 scores after dapagliflozin and placebo treatment. The McNemar test was used to assess regression in risk category. RESULTS: A total of 40 participants were randomized and 32 completed the trial with intact proteomic measurements. Twenty-eight (88%) were men, the baseline mean (SD) age was 63.0 (8.3) years, mean (SD) diabetes duration was 15.4 (4.5) years, mean HbA1c was 73 (14) mmol/mol (8.8% [1.3%]), and median (interquartile range) UACR was 154 (94, 329) mg/g. Dapagliflozin significantly lowered CKD273 score compared with placebo (-0.221; 95% CI -0.356, -0.087; P = 0.002). Fourteen participants exhibited a high-risk pattern after dapagliflozin treatment compared with 24 after participants placebo (P = 0.021). CONCLUSIONS: Dapagliflozin added to renin-angiotensin system inhibition reduced the urinary proteomic classifier CKD273 in persons with T2D and albuminuria, paving the way for the further investigation of CKD273 as a modifiable kidney risk factor.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Curovic VR, Eickhoff MK, Rönkkö T, et al. Dapagliflozin Improves the Urinary Proteomic Kidney-Risk Classifier CKD273 in Type 2 Diabetes with Albuminuria: A Randomized Clinical Trial. Diabetes Care. 2022. PMID: 35998283. doi:10.2337/dc22-1157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。